10 finalists for Stem Cell Person of the Year 2016

scpoy-2016-finalistsThe voting on the 20 nominees for Stem Cell Person of the Year finished at midnight last night.

After more than 1,000 votes, we have the top 10 finalists.

These ten are some of the most remarkable people in the world of stem cells today. They have all had great impact, but in very diverse ways.

They run the spectrum from patient advocates to the President of CIRM to a host of top stem cell researchers. Patient advocates Ted Harada and Judy Roberson have the top two spots in terms of votes.

Now I have the tough task of picking just one winner as the Stem Cell Person of the Year. The awardee wins international recognition as the top outside the box thinker and positive impactor of the year and a $2,000 prize. You can read more about all the 20 people who were nominated here.

Vote now for your pick for Stem Cell Person of the Year 2016

Vote on your pick for the top stem cell outside the box thinker and positive impactor in 2016 from the 20 choices below. The top 10 vote getters will be finalists from which I will have the tough task of picking the one winner as Stem Cell Person of the Year along with the $2,000 prize and recognition.

You can vote once per day. The voting closes in 10 days on December 15th at 11:59pm Pacific Time. Read more about the 20 nominees here.

20 Nominees for Stem Cell Person of the Year 2016 Award

stem-cell-person-of-the-year-awardI received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks.

I’ve started an on-line vote where you can vote once per day for your favorite nominee(s) for Stem Cell Person of the Year. The top half or so of nominees getting the most votes will be the finalists from which I will choose the final winner, who receives the $2,000 prize and international recognition as a global leader in the stem cell and regenerative medicine field.

Past winners of the Stem Cell Person of the Year Award include the following:

  • Top stem cell scientist Jeanne Loring in 2015.
  • Pioneering vision and pluripotent stem cell clinical researcher, Masayo Takahashi in 2014.
  • Neural stem cell scientist and very effective Italian politician Elena Cattaneo in 2013.
  • Stem cell patient advocate Roman Reed in 2012.

Here are the 2016 nominees in alphabetical order by first name with some description of who they are and a bit of the words from the person(s) who nominated them in some cases. Where I could find a link to websites describing their accomplishments, I have provided those.

Amy Wagers, Professor at Harvard. She has a long track record of cutting edge research on stem cells including recently very provocative work on the role of stem cells in human aging and approaches to reversing aging.

Arnold Caplan, Professor at Case Western Reserve. He is often considered the “father” of the mesenchymal stem/stromal cell (medicinal signaling cell) field and has done important research on MSCs over many years.

Connie Eaves, Distinguished Investigator at Terry Fox Laboratory at UBC. She has a remarkable track record of innovative research on stem cells including both normal and cancer stem cells and a reputation as a fantastic mentor and leader in the field more generally. “Brilliant scientist with unmatched piercing view of science”.

Hiroshi Nagashima, Professor at Meiji University, Tokyo. “A true translational scientist (with a wicked sense of humor!)” He works in part on cloning technology and could revolutionize organ transplantation approaches leading to huge impact.

Jim Gass. Jim is a patient who suffered a stroke and then sought stem cell treatments to try to reverse some of the damage. Somewhere along the lines, one or more of the unproven stem cell therapies he received caused him to develop a spinal tumor. He had the courage to go public with his story and describe his experiences, potentially risking litigation. “A gutsy man who has prevented others from getting injured.”

John Pimanda, Associate Professor of Medicine and Stem Cell Biology, UNSW Australia. He researches transcriptional regulation of adult stem cells and now the use of fat stem cells for spine injury.

Judy Roberson. She is a tireless Huntington’s Disease (HD) advocate, always working to make a positive difference. “She is a straight shooter who will tell you what she thinks and work to make it a reality.”

Jun Takahashi. He is a Professor at CiRA and pluripotent stem cell biology researcher. Jun has done pioneering IPSC research and is working to start a very exciting Parkinson’s Disease clinical trial using IPSC in Japan.

Margaret Goodell, Professor at Baylor College of Medicine. She is an internationally respected scholar in the stem cell field. She conducts cool, innovative research on transcriptional and epigenetic regulation of hematopoietic stem cells and how this goes awry in leukemias.

Mike West. Often mentioned as one of the founders of the regenerative medicine field, he is the leader of BioTime and is a thought leader in the field. “Mike knows all about taking risks in regenerative medicine leading to big, positive leaps forward.”

Nissim Benvenisty, Professor of Genetics at the Hebrew University of Jerusalem. He is a super-prolific, long-time stem cell researcher. His latest work this year was on revolutionary production of haploid ES cells.

Oliver Brustle, Professor and Director of the Institute of Reconstructive Neurobiology and Professor of Reconstructive Neurobiology at the University of Bonn Medical Center. He conducts innovative neural stem cell research and is a globally respected stem cell leader.

Randy Mills, President and CEO of CIRM. He has been a leader in stem cell biotech for years and has shaken things up at the helm of CIRM with a much more translational emphasis. “Randy has CIRM on track to meaningful clinical outcomes in a way that I cannot imagine another leader could have achieved. The outcome will change the world.”

Richard Ambinder, Johns Hopkins Hospital. Professor Ambinder has done pioneering work in the area of stem cells and viruses, including HIV, as well as stem cells for patients with hematopoietic malignancies. A scientist with a prodigious publication record of high-impact papers.

Robert Lanza. He has been a regenerative medicine leader for, what, decades? Long time scientific leader behind ACT and then its new incarnation as Ocata, which was purchased by Astellas and he leads global regenerative medicine at Astellas.”We expect something new and big from Bob at every turn”.

Sally Temple, Scientific Director, Co-Founder, and Principle Investigator at the Neural Stem Cell Institute. She is also the President of ISSCR. Scholar and innovative researcher in the stem cell field with a focus on stem cells in the brain. Past MacArthur Fellow. “One of the brightest developmental biologists in the world and a natural leader.”

Sheng Ding, Senior Investigator, Gladstone Institute of Cardiovascular Disease. Dr. Ding has done some of the most creative and impactful research in the stem cell field to date, and continues to crank out new discoveries in particular related to chemical reprogramming. He also has co-founded a number of exciting biotechs including Fate Therapeutics. “He has been a positive leader in the stem cell field, and his outside-of-the-box thinking has greatly enhanced our collective efforts to advance the field.”

Shoukhrat Mitalipov, Professor at ONPRC and OHSU. Shoukhrat is a top researcher in the stem and germ cell arenas of research including cloning and mitochondrial transfer, with cutting edge high impact papers published every year. “Fearless and one of the premier innovators in the field”.

Ted Harada (posthumous). Ted was one of the most prominent patients participating in a stem cell clinical trial ever. He fought for patients and efforts such as right to try every step along the way, and brought people together in the field. You can see his obituary and tributes here.

Theresa Liao. Powerful advocate for the use of stem cells to treat recessive dystrophic epidermolysis bullosa (RDEB). Through relentless advocacy she has made a profound difference in this area of clinical research.  “A parent and visionary patient advocate.”

Lorenz Studer named 2015 MacArthur Fellow for stem cell work

The annual selection of MacArthur Fellows highlights creative leaders in a variety of fields. The fellows receive $625,000 with no strings attached.

Stem cell biologists have been selected on a regular basis over the years as MacArthur Fellows including Kevin Eggan (2006), Sally Temple (2008), and Yukiko Yamashita (2011).

This year’s group of two-dozen 2015 MacArthur Fellows includes stem cell biologist Lorenz Studer (see video above). You can learn much more about Dr. Studer’s work on his lab’s home page here.

Lorenz Studer

Screenshot from MacArthur video

The announcement highlights Studer’s work on creating dopaminergic neurons (the type lost in Parkinson’s Disease) from stem cells including in particular from IPS cells, and broader implications of his work to neuro conditions:

“Lorenz Studer is a stem cell biologist pioneering a new method for large-scale generation of dopaminergic neurons that could provide one of the first treatments for Parkinson’s disease and prove the broader feasibility of stem cell–based therapies for other neurological disorders.”

Big congrats to Dr. Studer!

This is good news for the overall stem cell field as well.

Sally Temple on adult RPEs for vision impairment, IND, & more

adult RPEsAt the recent RPI stem cell and bioengineering meeting, the Neural Stem Cell Institute’s Sally Temple talked about her group’s intriguing retinal pigmented epithelial cell (RPE) research.

With the broad focus of attention in the world of RPEs mostly on those derived from either human ESC or IPSC, it was exciting to here about the adult RPEs that Temple’s group has isolated and characterized (e.g. see this paper).

Although only about 3% of cells isolated from the human retina turn out to be retinal stem cells, Temple reported that they can be scaled to provide plenty of potential doses (see below).Sally Temple cells

One of the remarkable things about these stem cells is that they can make beautiful RPEs and also perhaps through some kind of EMT, they can generate cells of the mesenchymal lineage (see image below).

They are hoping to have an IND in the next couple years. I’m very curious how the adult RPEs compare to those made from pluripotent stem cells.retinal pigmented epithelial stem cells

I also asked Sally after the meeting to give a big picture perspective on this work:

“My experience in translating the discovery of RPE stem cells towards a therapeutic for age-related macular degeneration is that it is an intensive team effort. You really need to have experts in different aspects of the science, animal modeling, safety testing, regulatory science and clinical disease, both doctors and patients, all working together. Our experience has been amazing, everyone on the team is working so hard to create this new therapeutic. You also need substantial funding, and we have to thank the NYS NYSTEM program for creating this incredible opportunity via their clinical translation program.”

I’m curious what the pluripotent stem cell-derived RPE fans (e.g. Ocata, the IPSC RPE team in Japan led by Masayo Takahashi, etc.) think of this adult RPE approach.